Elevated levels of IL-6 in serum of COVID-19 patients after Tocilizumab treatment
Scandinavian Journal of Immunology
; 95(6), 2022.
Article
in English
| EMBASE | ID: covidwho-1968192
ABSTRACT
The COVID-19 pandemic has had a dramatic effect on the quality of life worldwide. It is caused by the SARS-CoV-2 virus and the main symptoms include myalgia, headache, and non-productive cough. Tocilizumab (TCZ) is a monoclonal antibody antagonist for the Interleukin-6 (IL-6) receptor. TCZ has shown significant efficacy in patients with severe COVID-19 because of the upregulation of IL-6 in their serum that has a correlation to severe disease and mortality. Here, we show how levels of IL-6 in serum of TCZ treated COVID-19 patients in the intensive care unit (ICU) is elevated in response to the TCZ treatment. Five COVID-19 patients that were administered TCZ in the ICU had serum samples taken at least two timepoints, before and after TCZ administration. Serum cytokine and antibody levels were analysed by multiplex. The study was approved by The National Bioethics Committee (VSN-20-169) and the Data Protection Authority. As expected, all ICU patients were in cytokine storm with significantly high levels of various inflammatory mediators including IL-6 (ranging from 4-196 pg/ml) before TCZ administration. Interestingly, despite of overall clinical improvements TCZ administration led to a significant surge of IL-6 levels, resulting in a 213-fold increase after treatment (range from 1940-9067 pg/ml). In contrast to IL-6 none of the other inflammatory biomarkers had the same pattern. However, IL-10 was downregulated in 4/5 individuals. Finally, all patients demonstrated normal antibody response in addition to high IgA levels against receptor binding domain and spike 1. These findings demonstrate that receptor blockage of cytokines can lead to a significant surge of its corresponding cytokine with unclear, but potentially important clinical significance.
biological marker; cytokine; endogenous compound; immunoglobulin A; interleukin 10; interleukin 6; tocilizumab; adult; adverse drug reaction; antibody response; bioethics; clinical article; conference abstract; controlled study; coronavirus disease 2019; cytokine storm; data protection; drug therapy; female; gene expression; human; human tissue; immunoglobulin blood level; intensive care unit; male; mortality; receptor binding; side effect; spike; upregulation
Full text:
Available
Collection:
Databases of international organizations
Database:
EMBASE
Language:
English
Journal:
Scandinavian Journal of Immunology
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS